Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
A phase 2 trial of Selinexor, Daratumumab, Lenalidomide in multiple myeloma, run by US Oncology Research, active and no longer recruiting.
Overview
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma is a phase 2 interventional study registered as NCT04782687 by US Oncology Research, with 73 participants enrolled, started 2021-09-10 and due to reach its primary completion in 2026-05-31. Interventions recorded: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide. Conditions listed: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Selinexor, Daratumumab, Lenalidomide, Multiple myeloma.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TrialA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TrialA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TrialCEPHEUS
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TrialA Study of Daratumumab
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TrialA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
Shares Daratumumab, Lenalidomide, Multiple myeloma.